TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Delveinsight
Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 20 pharmaceutical companies are developing new treatments for celiac disease, moving beyond the current gluten-free diet management approach. Clinical trials are exploring innovative therapies targeting various mechanisms to improve patient outcomes.

Insights
NVDA   neutral

Slower growth rate compared to Palantir, but more stable with a more reasonable price-to-earnings multiple and lower investment risk


SNY   positive

Actively developing Amlitelimab, an OX40 ligand inhibitor in Phase II clinical trials